Latest news
How Surging Revuforj and Niktimvo Sales and Narrowing Losses Could Shape Syndax Pharmaceuticals (SNDX) Investors - Yahoo FinanceYahoo Finance · Fri, 07 Aug 2026 14:18:19 GMTSurging Revenue And Narrower Losses Might Change The Case For Investing In Syndax Pharmaceuticals (SNDX) - SahmSahm · Wed, 05 Aug 2026 07:00:00 GMTSNDX: Q2 revenue surged 92% year-over-year, driven by strong Revuforj and Niktimvo growth - TradingViewTradingView · Tue, 04 Aug 2026 23:20:53 GMT